Certain Causes of Neonatal Death. IV. Massive Pulmonary Haemorrhage

Fedrick, Jean; Butler, N

doi:10.1159/000240366

Cited by 33 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Although the incidence of DAH is difficult to estimate, DAH was the principle cause of death in about 9% of neonatal autopsies. 2 When mechanical ventilator support was required, DAH mortality exceeded 50% in immunocompromised patients. 3 The therapeutic options for acute intervention in DAH are limited and frequently unsuccessful.…”

mentioning

confidence: 99%

Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage

Bafaqih

Chehab

Almohaimeed

et al. 2015

Annals of Saudi Medicine

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVESDiffuse alveolar hemorrhage (DAH) is a life threatening condition with very limited, often unsuccessful, therapeutic options. This study aimed at exploring the feasibility and efficacy of nebulized tranexamic acid TXA (n-TXA) and nebulized recombinant factor VIIa (n-rFVIIa) when used in a two-step therapy protocol in children with intractable DAH in a pediatric intensive care unit.METHODSIn a prospective trial, n-TXA (250 mg/dose for children <25 kg and 500 mg/dose for children >25 kg) was administered to 18 children (median age [interquartile range]; 24.0 months [11.3, 58.5]) with intractable DAH. N-rFVIIa (35 μg/kg/dose for children <25 kg, and 50 μg/kg/dose for children >25 kg) was added if no or minimal response was seen after 3 to 4 doses (18 to 24 hours) of n-TXA.RESULTSDAH was stopped in 10 (55.6%) children with n-TXA alone within 24 hours of therapy. Documented concomitant respiratory infection showed a significant negative association with response to n-TXA in a stepwise regression analysis (OR=0.06; 95% CI=0.01–0.74). In the other 8 (44.4%) children, n-rFVIIa was added due to n-TXA failure. Six (75.0%) showed complete cessation of DAH, while two children failed to respond with the addition of n-rFVIIa (25.0%). None of the children who responded to therapy showed recurrence of DAH after therapy termination. No complications related to therapy were recorded.CONCLUSIONSn-TXA and n-rFVIIa were effective and safe when used in a two-step-therapy protocol to control intractable DAH in pediatric patients in intensive care settings. This therapy modality warrants further exploration through larger multicenter clinical trials.

show abstract

mentioning

confidence: 99%

Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage

Bafaqih

Chehab

Almohaimeed

et al. 2015

Annals of Saudi Medicine

View full text Add to dashboard Cite

show abstract

Pulmonary Hemorrhage

Tomaszewska¹,

Stork²,

Minich³

et al. 1999

Arch Pediatr Adolesc Med

View full text Add to dashboard Cite

To describe the clinical course, neonatal morbidity, and neurodevelopmental outcomes of very lowbirth-weight (Ͻ1500 g) children who develop pulmonary hemorrhage. Design: A retrospective case-control study in which 58 very low-birth-weight infants who developed pulmonary hemorrhage during 1990 through 1994, of whom 29 survived, were each matched to the next admitted infant who required mechanical ventilation for respiratory distress syndrome and was of the same sex, race, and birth weight (within 250 g). Setting: A regional tertiary neonatal intensive care unit and follow-up clinic for high-risk infants at

show abstract

Intrauterine Growth Retardation

Miller¹

1981

Am J Dis Child

View full text Add to dashboard Cite

Certain Causes of Neonatal Death. IV. Massive Pulmonary Haemorrhage

Cited by 33 publications

References 12 publications

Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage

Pilot trial of a novel two-step therapy protocol using nebulized tranexamic acid and recombinant factor VIIa in children with intractable diffuse alveolar hemorrhage

Pulmonary Hemorrhage

Intrauterine Growth Retardation

Contact Info

Product

Resources

About